Keightley Amen

Articles by Keightley Amen

Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 8, 2024
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Keightley AmenChronic Lymphocytic Leukemia | September 5, 2023
The results provide evidence of the real-world effectiveness of ibrutinib in an insured U.S. population.
Keightley AmenMeeting News | September 5, 2023
A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma.
Keightley AmenMyelofibrosis | September 5, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Keightley AmenMyeloproliferative Neoplasms | February 8, 2024
The phase II MANIFEST study suggested that pelabresib could be beneficial in myelofibrosis.
Keightley AmenMyelofibrosis | September 5, 2023
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
Keightley AmenMyeloproliferative Neoplasms | February 8, 2024
The case-control study used information from the Veterans Affairs Informatics and Computing Infrastructure database.
Keightley AmenMyelofibrosis | September 5, 2023
Researchers followed the patients for three years after their final dose of luspatercept.
Keightley AmenMyelofibrosis | September 5, 2023
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Keightley AmenMyelofibrosis | September 5, 2023
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
Keightley AmenIndolent B-Cell Lymphoma | September 5, 2023
Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects.
Keightley AmenMantle Cell Lymphoma | September 5, 2023
These findings suggest that real-world outcomes of brexu-cel are consistent regardless of prior BTK inhibition, brexu-cel.
Keightley AmenAggressive B-Cell Lymphoma | September 5, 2023
Targeted induction immunochemotherapy with ibrutinib or lenalidomide and R-MPV is feasible, according to the researchers.
Keightley AmenMyeloproliferative Neoplasms | September 5, 2023
In patients with Afib, MPNs are linked to an increased risk of hospital readmissions for bleeding and arterial thrombosis.
Keightley AmenMyeloproliferative Neoplasms | December 12, 2022
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Keightley AmenMeeting News | December 11, 2022
A recent study evaluated patients with rare myeloid neoplasms who had NPM1 mutations.
Keightley AmenMeeting News | December 11, 2022
The IPSS-M Risk Stratification Model led to reclassification of almost half of patients with hypoplastic MDS.
Keightley AmenMyelodysplastic Syndromes | December 11, 2022
The number of cells with chromosomal abnormalities was significantly associated with clinical features and outcomes in MDS.
Keightley AmenMeeting News | December 11, 2022
SX-682 was effective and well tolerated at a dose of 200 mg twice daily in patients with MDS.